ABSTRACT
INTRODUCTION
divergence is the primary cause of biased data loss (75) . Following the selection of a guide sequence, reads 216 were mapped and aligned using the mapping algorithm previously described (76). During mapping site indexes 217 in relation to HXB2 were also maintained. Next to reduce diversity between reads and reference, a consensus 218 was generated across each site of the guide sequence and reads re-mapped to this final consensus template.
219
Reads spanning the 3'end of Gag, PR, RT, and INT were then translated and assembled for genotyping. 
230
In addition, for each dataset, reads spanning amino acid positions (i) 50 to 85 in the protease (HXB2 2,400 to 231 2,508), (ii) 180 to 215 in the RT (HXB2 3, 087 to 3, 195) , (iii) 130 to 165 in the integrase (HXB2 4,617 to 4,725), and
232
(iv) 1 to 35 in the V3 region (HXB2 7,110 to 7,217) were extracted, truncated and translated for phylogenetic 
313
Estimation of the intrinsic error rate of the assay. Point mutations, insertions, and deletions (indels) can be 314 introduced in the PCR amplification and sequencing steps of any deep sequencing-based assay (84). Therefore,
315
it was important to calculate the intrinsic (combined) error rate of our novel HIV-1 genotyping and coreceptor 316 tropism assay since this value could affect the practical limit of detection of the assay. For that, the pNL4-3-317 hRluc plasmid containing the entire genome of the wild type HIV-1 NL4-3 strain (69) was transformed into
318
Electrocomp TOP10 bacteria (Invitrogen). One bacteria colony was grown overnight in 10 ml of bacteria culture,
319
plasmid DNA was purified, and transformed again into bacteria. Ten individual, theoretically identical, bacteria 320 colonies were used for the direct PCR amplification of the gag-p2/NCp7/p1/p6/pol-PR/RT/IN and env-C2V3 321 fragments ( Fig. 2A) , and sequenced using the same protocol utilized with the clinical samples. The quality of the (Q20), which provides a base call accuracy of 99% (i.e., a 1 in 100 probability of an incorrect base call). The 
330
Although all ten NL4-3 clones were expected to have no mutations (i.e., point mutation and/or indels)
331
relative to the pNL4-3-hRluc reference sequence, a number of errors were observed throughout the 332 p2/NCp7/p1/p6/pol-PR/RT/IN and V3 regions, ranging from 0% to 29% (mean 0.39%) and 0% to 9.5% (mean 333 0.37%), respectively (Fig. 2C) . The average error frequency due to point mutation was 0.17% (range 0% to 2.5%) 334 and 0.12% (0% to 0.3%) for the p2/NCp7/p1/p6/pol-PR/RT/IN and V3 regions, respectively, whereas the average 335 error rate associated with indels was 0.22% (range 0% to 28%) and 0.25% (0% to 9.2%). Most of the positions 336 with a total (point mutation + indels) error rate above 1% corresponded to the last nucleotide of a 337 homopolymeric region, defined as four or more identical consecutive nucleotides (data not shown). Some of 338 these nucleotide positions corresponded to codons that have been associated with resistance to antiretroviral 339 drugs, e.g., L10 in the protease (3.5%), K101 in the RT (3%), and G193 in the integrase (10.5%) or with coreceptor 340 tropism, e.g., position 11 in the V3 region (2.6%) (Fig. 2D, Table 2 ). Interestingly, most of the errors in these 341 (homopolymeric) positions corresponded to indels, with a limited number of point mutation errors, e.g., L10
342
(3.3% vs. 0.22%), K101 (2.7% vs. 0.24%), G193 (9.6% vs. 0.89%), and position 11 in the V3 (2.3% vs. 0.25%), 343 respectively (Table 2 ). Therefore, considering that (i) the overall error rates for the gag-p2/NCp7/p1/p6/pol-344 PR/RT/IN and env-V3 regions were 0.39% and 0.37%, respectively, (ii) the point mutation error rates were below on November 12, 2017 by guest http://aac.asm.org/
Downloaded from
Tool Suite identifies and filters out the indels, it was reasonable to define a frequency of 1% as the minimum measure of success for any deep sequencing-based assay depends on its ability to generate the maximum 
366
V3 region, respectively) or 96 samples (4,485; 1,612 to 7,274 and 1,017; 966 to 1,070).
368
As described above, we calculated the error rate of the HIV-1 genotyping and coreceptor tropism assay to be 369 below 1% and incorporated this error-defined cutoff into the evaluation of the analytical sensitivity and limit of detection for minority HIV-1 variants. For that, we evaluated extensively the analytical sensitivity of the test to 371 detect and quantify drug resistance mutations (gag-p2/NCp7/p1/p6/pol-PR/RT/IN) and non-R5 variants (env-V3) 372 within mixtures of viral populations. First, we sequenced five plasmid mixtures that contained one or two drug 373 resistance mutations in the RT-and/or IN-coding regions at a frequency of 5% or 10% (i.e., mixture of plasmids 374 containing the respective mutations with a plasmid comprising the wild-type HIV-1 HXB2 sequence). As shown in
375
Supplemental Figure S2 , all mutations were detected and quantified at the expected proportions, including 376 those at a frequency of 5% of the total population. Next, in order to quantify more accurately the analytical 377 sensitivity of the assay, we mixed DNA from a plasmid containing a patient-derived multidrug-resistant gag-378 p2/NCp7/p1/p6/pol-PR/RT/IN fragment in the X4 HIV-1 NL4-3 backbone (08-180)(68) with DNA from a plasmid 379 containing the genome of the wild-type HIV-1 NL4-3 virus carrying the env gene from the R5 HIV-1 YU2 virus (69).
380
Plasmid DNA was quantified and dilutions used to prepare eight mixtures containing the X4 multidrug-resistant 381 08-180 plasmid at 0%, 0.1%, 1%, 2%, 3%, 5%, 10%, and 100% at a final concentration of 0.1 ng/ml. This total 382 plasmid concentration (0.1 ng/ml or 100,000 femtograms/ml) theoretically allowed the detection of 100 fg of 
